<DOC>
	<DOCNO>NCT01206517</DOCNO>
	<brief_summary>This study open label , sequential-group , two site , multiple dose escalate study sublingual administer asenapine pediatric population schizophrenia bipolar I disorder ; one study cohort ( 3a ) participant condition treatable chronic antipsychotic medication also enrol . Participants receive single sublingual placebo dose Day -1 , follow multiple sublingual dos asenapine twice daily ( b.i.d . ) 6 day ( Cohorts 1 2 ) , 7 day ( Cohort 3b-d ) , 11 day ( Cohort 3a ) , final daily administration Day 7 ( Cohorts 1 2 ) , Day 8 ( Cohort 3b-d ) Day 12 ( Cohort 3a ) .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetics , Safety Tolerability Sublingual Asenapine Pediatric Population With Schizophrenia Bipolar I Disorder ( P06522 AM1 )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Asenapine</mesh_term>
	<criteria>Inclusion Criteria For participant Cohorts 1 , 2 , 3b , 3c 3d : Diagnosis schizophrenia bipolar I disorder A schizophrenic participant must diagnosis current schizophrenia paranoid disorganize , catatonic , undifferentiated subtype determine structured clinical interview screen A bipolar I disorder participant must primary diagnosis bipolar I disorder , current episode manic , mixed determine structured clinical interview screen For participant Cohort 3a : Documented history schizophrenia , bipolar disorder , autism , conduct disorder , oppositional defiant disorder , condition chronic use antipsychotic medication ( e.g , risperidone , olanzapine , aripiprazole , haloperidol ) warrant and/or administer All participant : Must least 10 old 17 year age day first asenapine dosing ( Cohort 3 ) ; Cohort 1 2 subject least 10 old 11 year age day first asenapine dosing Must able willing sign inform assent require local regulation study participation able adhere dose visit schedule parent/authorized legal representative ( ) able willing sign inform consent , fluent language inform consent Must caregiver identify responsible person consider reliable investigator agree provide support subject ensure compliance trial treatment , outpatient visit , protocol procedure Must fluent language investigator , trial staff ( include raters ) inform assent Must willing discontinue psychotropic medication treatment period except specify protocol Have discontinue use strong inhibitor inducer cytochrome P450 ( CYP ) 1A2 and/or CYP2D6 ( e.g . fluvoxamine , citalopram , fluoxetine , paroxetine , omeprazole , rifampicin ) betablockers , apply washout period 5 half live 7 day , whichever long , AND stabilize noninteracting alternative medication ( i.e . medication interact asenapine pharmacokinetics ) 2 week prior baseline medical condition require Clinical laboratory test ( complete blood count [ CBC ] , blood chemistry , urinalysis ) must within normal limit clinically acceptable investigator , discussion Sponsor follow agreement Sponsor 's medical monitor Screening 12 lead electrocardiogram ( ECG ) conduction interval vital sign recording ( oral body temperature , systolic/diastolic blood pressure pulse rate ) must clinically acceptable accord investigator , discussion Sponsor follow agreement Sponsor 's medical monitor If male , nonvasectomized , must agree use condom spermicide ( marketed country ) abstain sexual intercourse , trial 3 month stop medication Female participant must : If unsterilized , use medically accepted method contraception 3 month ( abstain sexual intercourse ) prior screen period , agree use medically accept method contraception trial ( include screen period prior receive trial medication ) 2 month stop trial medication . An acceptable method contraception include one following : stable oral , transdermal , injectable , sustainedrelease vaginal hormonal contraceptive regimen without breakthrough uterine bleed 3 month prior Screening ; addition , study use condom and/or spermicide ( marketed country ) intrauterine device ( insert least 2 month prior Screening visit ) ; addition , study use condom and/or spermicide ( marketed country ) Note : Vasectomy partner consider sufficient contraception one 2 method list must use Females currently sexually active must also consent use one accept method contraception become sexually active participate study condom ( male female ) spermicide ( market within country ) , diaphragm cervical cap spermicide ( market within country ) condom ( male ) , Exclusion Criteria The participant exclude entry ANY criterion list meet baseline The participant : Is pregnant , intend become pregnant ( within 3 month end study ) , breastfeed In opinion investigator , able participate optimally study Has uncontrolled , unstable clinically significant medical condition ( e.g. , renal , endocrine , hepatic , respiratory , cardiovascular , hematologic , immunologic , gastrointestinal cerebrovascular disease , malignancy ) may interfere interpretation pharmacokinetic , safety tolerability evaluation opinion investigator Has history infectious disease within 4 week prior drug administration opinion investigator , affect subject 's ability participate trial Is positive hepatitis B surface antigen , hepatitis C antibodies human immunodeficiency virus ( HIV ) Has positive screen drug high potential abuse ( Screening period clinical conduct trial ) Has history psychiatric personality disorder opinion investigator sponsor , affect subject 's ability participate trial Has history neuroleptic malignant syndrome Has diagnosis mental retardation organic brain disorder Has primary diagnosis schizophrenia bipolar I disorder , current episode manic mixed , primarily responsible current symptom functional impairment ; exclusion applicable participant Cohort 3a Has diagnosis psychotic disorder behavioral disturbance think substance induce due substance abuse Has current ( past 6 month ) substance alcohol abuse dependence ( exclude nicotine caffeine ) Has history tardive dyskinesia tardive dystonia If attentiondeficit/hyperactivity disorder ( ADHD ) , stable dose stimulant ( e.g . amphetamine , methylphenidate ) last 3 month ( participant take stimulant last month exclude ) Has history alcohol drug abuse past 2 year Has donate blood past 60 day Has previously receive asenapine Is imminent risk selfharm harm others , investigator 's opinion base clinical judgment Report Screening , suicidal ideation , suicidal behavior past 6 month Is currently participate another clinical study participate clinical study ( e.g. , laboratory clinical evaluation ) within 30 day baseline Is part study staff personnel family member study staff personnel Has demonstrate allergic reaction ( eg , food , drug , atopic reaction asthmatic episode ) , opinion investigator sponsor , interfere ability participate trial Smokes 10 cigarette equivalent tobacco use per day Has history malignancy</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>asenapine</keyword>
	<keyword>pediatric schizophrenia</keyword>
	<keyword>bipolar I disorder</keyword>
</DOC>